Add-on Acquisition • Business Services

DoseMe Acquires Firstline Clinical

On November 3, 2025, DoseMe acquired business services company Firstline Clinical

Acquisition Context

This is DoseMe’s 1st transaction in the Business Services sector.
This is DoseMe’s 1st transaction in Canada.
This is DoseMe’s 1st transaction in British Columbia.

Explore All 10010 Add-on Acquisition Business Services Deals - Search the Database Free

M&A Deal Summary
Date	November 3, 2025
Target	Firstline Clinical
Sector	Business Services
Buyer(s)	DoseMe
Deal Type	Add-on Acquisition

Target Company

Firstline Clinical

Vancouver, British Columbia, Canada

Firstline Clinical provides a clinical decision support platform focused on infectious disease and antimicrobial stewardship. Firstline Clinical partners with hospitals, health systems, and public health organizations to deliver localized treatment guidelines and evidence-based prescribing information at the point of care. Firstline Clinical was founded in 2013 and is headquartered in Vancouver, British Columbia.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

DoseMe

Jupiter, Florida, United States

Category	Company
Founded	2014
Sector	Software

DESCRIPTION

DoseMeRx provides a cloud-based clinical decision support platform used by healthcare organisations to individualise medication dosing through Bayesian modelling. DoseMe’s software assists pharmacists and clinicians in optimising therapeutic drug monitoring for medications such as vancomycin and aminoglycosides. DoseMeRx was founded in 2014 and is headquartered in Jupiter, Florida.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Business Services	1 of 1
Type: Add-on Acquisition	1 of 1
State: British Columbia	1 of 1
Country: Canada	1 of 1
Year: 2025	1 of 1

Explore Related M&A Activity

Business Services M&A - Add-on Acquisition M&A Deals - British Columbia M&A - Canada M&A - 2025 M&A